| INTRODUC TI ON
Bladder cancer is the fourth most common male cancer and the ninth female cancer in Western countries and the USA, and the highest incidence rates in men are noted in countries from Southern Europe, North America, Northern Africa and Western Asia. 1, 2 In Taiwan, there is an unusually high incidence of bladder cancer in the black-foot-disease endemic area located on the southwest coast due to chronic arsenism, 3 and upper tract urothelial carcinoma (UTUC) due to aristolochic acid nephropathy. 4 At initial diagnosis, approximately 70%-80% of bladder cancer cases are non-muscle invasive. Most of these (~70%) easily recur, and approximately 15% may progress to muscle-invasive diseases despite endoscopic resection and adjuvant intravesical therapy. 5 In contrast, 20%-30% of bladder cancer cases are muscle-invasive, advanced or metastatic tumors upon diagnosis. Progression of cancer to metastatic disease is accompanied by an altered antioxidant expression profile, resulting in a net increase in the production of reactive oxygen species (ROS). 6 Owing to the limited therapeutic progress in recent decades, choices of radical cystectomy or bladder-sparing tri-modal therapy were the mainstream for patients with muscleinvasive disease. Despite these, half of all patients with advanced disease die of metastatic disease within 5 years. Until recently, several immune checkpoint inhibitors have gained US Food and Drug Administration approval for treating advanced or metastatic urothelial carcinoma, 7, 8 there is still 70%-80% patients presenting with primary, adaptive and acquired resistance to cancer immunotherapy. 9 Therefore, it is necessary to explore more regulatory mechanisms involved in human bladder cancer.
Prothymosin-α (PTMA) (usually isoform 1 or 2) is a small, acidic, nuclear protein that plays a pivotal role in a number of biological activities, including cellular (i.e. apoptosis, proliferation, chromatin decondensation or transportation) or immunological functions (i.e. tumor-specific T-lymphocyte response, interleukin-2 receptor expression or T[H]1-type immune responses). [10] [11] [12] [13] [14] [15] Recently, two new PTMA variants (iso b and pseudogene 7) lack of nuclear localization signal (NLS) were isolated and identified from CD8 + T cells and cervicovaginal lavage with potent anti-HIV-1 activity, which were suggested to be innate immune mediators involved in immune surveillance. [16] [17] [18] [19] [20] PTMA can induce the import of Kelch-like ECHassociated protein 1 (Keap1) into the nucleus to inhibit nuclear factor erythroid 2-related factor 2 (Nrf2)-mediated antioxidant response through Nrf2 degradation. 21 From our previous studies, we found that not only PTMA could be detected in the nucleus of the tumor cell, but also in the cytoplasm. The loss of nuclear PTMA (cytoplasmic or null expression pattern) predicts shorter progression-free survival in superficial bladder cancer and UTUC. 22, 23 These findings prompted us to explore the molecular and regulatory mechanisms of PTMA expression involved in human urothelial carcinoma. 36 Recently, TRIM21 was reported to be able to interact with and ubiquitinate p62 and prevent p62 dimerization and Keap1 sequestration, which downregulates the Nrf2 redox pathway. 37 In the current study, we demonstrated that the loss of nuclear PTMA is an unfavorable prognostic factor for disease relapse in human bladder cancer, in which nuclear PTMA could enhance PTEN transcription and mRNA expression through binding to the PTEN promoter and interacting with TRIM21, which can downregulate p62 and then Nrf2 expression in human bladder cancer.
| MATERIAL S AND ME THODS

| Cells
Seven human cell lines, including immortalized urothelial cell line (SVHUC), bladder cancer cell lines (TSGH8301, T24, J82, TCCSUP, BFTC905 and HT1197), renal pelvis tumor cell line (BFTC909) and prostate cancer cell line (PC3) were cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum, 2 mM lglutamine and 50 μg/mL gentamicin, except minimum essential medium for HT1197. Once cell growth reached 80%-90% confluence, cells were trypsinized for subsequent experiments, including total RNA extraction, western blotting and xenograft growing in SCID mice.
| Plasmid construction and lentivirus production
The full-length fragment and deleted nuclear localization signal (∆NLS) of the human PTMA gene were cloned into the lentiviral vector (pWPXL-enhancer-human WT PTMA and pWPXL-enhancerhuman ΔNLS PTMA). The human PTMA protein has a bipartite NLS, KKQK (residues 101-104). 38 After co-transfection of these two plasmids with the pMD2.G vector into 293 cells, the supernatants containing the lentiviruses were collected and stored for future experiments. After that, J82 cells were infected with the lentivirus carrying the indicated gene, and then three J82 transfectants were collected with cell sorting of the existence of green fluorescent protein.
| Analysis of the cDNA differential array
We performed a cDNA differential array using three J82 transfect- Primers for human PTMA and PTEN are shown in Table S1 . The − ΔΔC t method 40 was utilized to measure relative changes in mRNA levels examined by qRT-PCR experiments, after normalizing transcript levels of each gene by levels of β-actin as internal controls.
Western blotting and immunoprecipitation assays were performed as per our previous studies. 41 Protein ( 
| In vivo ubiquitination assay
This assay was similar to that in our previous study. 42 In brief, input fractions as indicated were prepared using RIPA buffer. His-tagged protein was pulled down using Dynabeads ® His-Tag Isolation, Pulldown kit (#10103D; Life Technologies, Carlsbad, CA, USA).
Bound material was eluted from the beads, collected and subjected to SDS-PAGE and western blot analyses.
| In vivo tumor growth study
Female (NOD-SCID, 6-8 weeks old) mice were s.c. injected with 1 × 10 6 J82 transfectants as indicated in 100 μL serum-free medium. Tumor formation and growth were recorded every other day for at least 60 days according to the "Guidelines for the Welfare of Animals in Experimental Neoplasia" (1998). Tumor volumes were calculated using the formula: length × (width) 2 × 0.45. Once tumor burden grows more than 2500 mm 3 , it is viewed as death from tumor.
At the end of this experiment, tumors were harvested for PTMA immunostaining.
| PTEN promoter cloning and reporter analysis
To clone PTEN promoter for the PTEN promoter activity analysis, we used PCR to amplify DNA fragments containing PTEN promoter genomic sequences from J82 cell genomic DNA. The primers used were PTEN_-1344/Kpn I (5′-ATGGTACCCTCGAGTCAGTGACACTGCTC-3′) and PTEN_-821/XhoI (5′-AACTCGAGCGCCGCCGTCTCTCATCT-3′) and derived from human genomic PTEN from -821 to -1344 according to GenBank accession number AF067844. Amplified DNA fragments were subcloned into the luciferase reporter vector pGL3 (Promega, Madison, WI, USA) according to the standard procedures. The in-frame integrity of the construct was confirmed by DNA sequencing. Cells were transfected using Lipofectamine (GIBCO BRL, Gaithersburg, MD, USA) in the presence of trace amounts of pCMV-β-gal. Luciferase assays were performed using the Luciferase Assay System (Promega), and activities were normalized to β-galactosidase activity.
| Chromatin immunoprecipitation (ChIP) assay
Cells lysates were prepared from three J82 transfectants. In brief, the specific antibodies used for immunoprecipitations were the anti-PTMA antibody (2F11; Alexis Biochemicals, San Diego, CA, USA) and a control antibody (rabbit IgG). After protein-DNA cross-links in the immunoprecipitates were reversed, the purified DNA was analyzed by PCR (35 cycles; 30 seconds at 95°C, 45 seconds at 58°C, 60 seconds at 72°C) with primers that detect sequences containing PTEN promoter (nucleotide number −523 to transcription starting site).
The PCR products were visualized on an ethidium bromide gel. I, Quantitative RT-PCR assay for PTMA mRNA expression, and J, ELISA for VEGF content in three J82 cell transfectants. K, Tumor growth curves of three J82 transfectant xenografts in SCID mice, and L, mice survival. ELISA, enzyme-linked immunosorbent assay; PTMA, prothymosin-α; RT-PCR, reverse transcription polymerase chain reaction; VEGF, vascular endothelial growth factor; VO, vector only; WT, wild type; ∆NLS, deletion of nuclear localization signal. *P < 0.05; **P < 0.01; ***P < 0.001
| Patient population and study samples
The study was undertaken with the approval and institutional over- 
| Immunohistochemistry (IHC)
Serial 5-μm sections were cut for either hematoxylin-eosin staining or IHC as performed in our previous study. 41 and then counterstained with hematoxylin. Samples were analyzed blindly by one pathologist. Any tumor specimens exhibiting more than 25% immunoreactive tumor cells within one high-power field were considered positive tumors as in our previous study. 
| Statistical analysis
The disease relapse analyzed in the study was the first event of tumor recurrence in the urinary bladder or tumor progression beyond the bladder. Disease-free survival was calculated AKT, Akt serine/threonine kinase; EMT, epithelial-to-mesenchymal transition; ESR1, estrogen receptor 1; GnRH, gonadotropin-releasing hormone; HGF, hepatic growth factor; IFN, interferon; MAPK, mitogen-activated protein kinase; PIP3, phosphatidylinositol 3,4,5 trisphosphate; SMAD, homologs of both proteins, mothers against decapentaplegic and SMA; TGF-β, transforming growth factor-β; WNT, Wnt/β-catenin signaling pathway of SCID mice ( Figure 1F-H) , as well as examining with qRT-PCR for mRNA levels ( Figure 1I ), mimicking nuclear, cytoplasmic or null PTMA expression. Our previous study has shown that J82 cells with ectopic WT PTMA expression exhibit higher growth rate and secrete less transforming growth factor (TGF)-β1 than do those with ∆NLS PTMA expression or control cells, 22 as well as less VEGF production in the current study ( Figure 1J ). In addition, ∆NLS PTMA expression can promote J82 xenograft growth in SCID mice and shorten mice survival as compared with WT PTMA or null PTMA expression ( Figure 1K ,L).
| WT PTMA protein binds to the PTEN promoter and enhances PTEN mRNA and protein expression
To further explore what kind of signaling pathway PTMA protein influences, the cDNA differential array was done with these three J82 transfectants and further analyzed by utilizing the online Metacore® software. The result showed that the top 10 signaling pathways influenced by PTMA protein include TGF-β1/smad-related EMT, PIP3-Akt, GnRH, estrogen receptor and interferon (IFN)-γ signaling (Table 1) . (Figure 2A,B) . In contrast, PTEN expression was decreased in TCCSUP cells while knocking down PTMA expression ( Figure 2C ). Further, using qRT-PCR and promoter assays, we found that J82 cells with ectopic WT PTMA expression exhibit both higher PTEN mRNA and PTEN promoter activity than those with ∆NLS PTMA protein expression or control cells ( Figure 2D,E) . The ChIP assay demonstrated that WT PTMA protein could bind to PTEN promoter region between -500 bp and transcriptional start site while ∆NLS PTMA protein cannot ( Figure 2F ).
| PTMA binds and orchestrates with TRIM21 to regulate Nrf2 expression through p62/ Keap1 signaling
To explore what kind of proteins PTMA binds to, we analyzed PTMA-bound proteins immunoprecipitated from BFTC905 cells (an E3-ubiquitin ligase) and others ( Figure S1 ). To examine the interaction between PTMA and TRIM21 protein and its associated molecular signaling, we first confirmed the physical interaction of PTMA with TRIM21 protein using an immunoprecipitation study in BFTC905 cells ( Figure 3A) . Also, we can detect TRIM21 protein expression in several human bladder cancer cells, as well as TRIM21-regulated Nrf2 expression ( Figure 3B ). By using imaging density analysis, we found a trend of negative correlation between PTMA and Nrf2 protein (P = 0.13). Figure 3C-F) .
Furthermore, both WT PTMA and ∆NLS PTMA can bind with TRIM21
and regulate Keap1 and Nrf2 expression differentially ( Figure S2 ). 
| Both TRIM21 and PTMA influence each other
Because TRIM21 is an E3 ubiquitin ligase, we further investigate whether PTMA can be regulated by TRIM21 through proteasomal ubiquitination. We found that TRIM21 can reduce both WT PTMA and ∆NLS PTMA protein expression as compared with the control Foxp3 protein, in which the ∆NLS PTMA protein is downregulated more than the WT PTMA protein ( Figure 4A ). The in vivo ubiquitination Figure 5E and Table S2) . Log-rank analysis demonstrated that nuclear PTMA is a favorable prognostic factor for disease-free survival ( Figure 5F ). PTEN mRNA is significantly higher in tumors with nuclear PTMA expression than in those with cytoplasmic or null PTMA expression ( Figure 5G ).
| Increased TRIM21 expression is associated with PTMA expression in human bladder cancer
Two serial sections of tissue microarrays containing 60 bladder tumors and 22 non-cancerous tissues were immunostained with TRIM21 and PTMA ( Figure 6A-H) . The results revealed that bladder tumors exhibit increased TRIM21 expression as compared with noncancerous tissues (P = 0.002) ( Figure 6I ). There is a weakly positive correlation between TRIM21 and PTMA expression in human bladder cancer, regardless of nuclear or cytoplasmic location ( Figure 6J ).
| D ISCUSS I ON
In the current study, we found that cytoplasmic PTMA expression or null PTMA expression is a poor prognostic factor for disease-free that is used not only for the ubiquitination of USP4 and IKB κB but also for its self-ubiquitination. 46 TRIM21 can monoubiquitinate IKB κB that will negatively regulate both nuclear factor-κB signaling and IFN-β production, and involve the ubiquitination of IRF3 and IRF8 to stimulate the transcription of cytokine genes in macrophages. 36 Recently, TRIM21 was reported to be able to interact with and ubiquitylate p62 that prevent p62 dimerization and Keap1 sequestration function, resulting in Nrf2 degradation. 37 In the current study, we found that ∆NLS PTMA could be more downregulated by Collectively, PTMA can enhance PTEN expression through increasing PTEN promoter activity and orchestrate with TRIM21 to regulate Keap1/Nrf2 expression in human bladder cancer, which can provide a direction for Nrf2-targeted therapy in human bladder cancer. 
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